Navigation Links
Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Date:2/6/2008

- Expands the Company's Clinical Stage Product Portfolio -

ANN ARBOR, Mich., Feb. 6 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced that it is has completed a global licensing agreement to make, develop and commercialize products under AstraZeneca's IP and know-how regarding the use of aromatase inhibitors (AI) in combination with estrogen and progestin to treat endometriosis. This agreement expands Meditrina's clinical stage product portfolio which currently includes Femathina(TM) (MPI- 674), an AI that Meditrina is repurposing for the treatment of several serious women's health conditions, including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB). Femathina recently completed a phase II clinical trial.

"We are pleased to expand Meditrina's product portfolio with this attractive phase II product opportunity addressing a serious unmet medical need in the area of women's health," said Holly Vene, COO and Vice President, Business Development, Meditrina Pharmaceuticals, Inc. "Providing safer and more effective treatment options for the millions of women who suffer from endometriosis is an objective that fits perfectly with Meditrina's focus and commitment to improving the reproductive health and well-being of women. While Meditrina will pursue development and registration of a product for the U.S. market, it will consider partnering the product in ex-U.S. markets at the appropriate time to ensure global access to this important technology."

Endometriosis is a serious medical condition where endometrial stroma and glands that are normally present in the uterine cavity are found in other parts of the body. Endometriosis lesions can be found anywhere in the pelvic cavity: on the ovaries, the fallopian tubes, on the pelvic sidewall, the uterosacral ligaments, the cul-de-sac, the Pouch of Douglas and in the rectal- vaginal septum.

The most common symptom o
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
11. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... FREMONT, Calif., Dec. 14 Vermillion, Inc. (Pink Sheets: ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice President, Research ... board of directors upon confirmation of Vermillion,s bankruptcy plan. ... and development experience in diagnostics and biotechnology," said Gail ...
... , , , NATICK, Mass., Dec. ... announced the completion of a public offering of $2 billion aggregate ... statement. The public offering consists of $850 million of 4.50 ... due January 2020 and $300 million of 7.375 percent notes due ...
... ... the delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move from sheet ... , ... December 14, 2009 -- ThermoFab, a US-based thermoforming company, has completed the delivery of ...
Cached Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:8/26/2014)... of harmful bacteria, biofilms make the treatment of ... biofilm pose a significant health risk due to ... biofilm-protected bacteria account for some 80 percent of ... to 1,000 times more resistant to antibiotics than ... have stumbled onto a magic bullet," said David ...
(Date:8/26/2014)... succeeded in obtaining an unprecedented view of a ... a range of neurological illnesses, including Alzheimer,s disease, ... associated with stroke. , The team of biologists ... Department of Energy,s Advanced Photon Source at Argonne ... the intact NMDA (N-methyl, D-aspartate) receptor should serve ...
(Date:8/26/2014)... endemic tree has for the last 31 years been incorrectly ... and small trees. A New Zealand botanist has completed a ... diversity behind what was long considered a single tree species. ... PhytoKeys . , Known to botanists as ... discoveries made in the north-western South Island of New Zealand ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3
... life in higher animals, vitamin D, once linked to only ... as a major player in contributing to overall human health, ... on vitamin D. In a paper published in the ... Nutrition , Norman identifies vitamin D,s potential for contributions ...
... Carolina State University is leading to a new kind ... from freshwater ponds, instead of from the sea. ... crabs look and taste just like their ocean-raised brethren. ... at historic lows since 2000. Dr. Dave Eggleston, director ...
... develop sustainable energy systems while reducing the harmful ... phased out over the next century. This optimistic ... technologies such as biomimetics and Dye Sensitized solar ... or storing solar energy, and nanocatalysis develops efficient ...
Cached Biology News:Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Turning freshwater farm ponds into crab farms 2Europe rallies behind nanotechnology to wean world from fossil fuels 2Europe rallies behind nanotechnology to wean world from fossil fuels 3Europe rallies behind nanotechnology to wean world from fossil fuels 4
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Biology Products: